Prehospital neuroprotectant in combination with post-arrival thrombolytic therapy for acute ischemic stroke. Secondary analysis of the FAST-MAG prehospital trial.

J Stroke Cerebrovasc DisJul 24, 2026 (epub)
Clinical ResearchNeurologyEmergency Medicine

Kristina Shkirkova, Sokena Zaidi, May A Kim-Tenser et al.

✦ AI-curated · Sources linked

In 30 seconds

This secondary analysis of the FAST-MAG trial evaluated the effects of prehospital magnesium sulfate versus placebo in patients with acute ischemic stroke receiving thrombolysis. The study included 401 patients, with 214 receiving magnesium. While magnesium showed a higher proportion of favorable outcomes in patients with NIHSS >15, overall 90-day outcomes did not demonstrate significant clinical benefit.

Key findings

  • In patients with NIHSS >15, the magnesium group had a higher proportion achieving favorable 90-day outcomes (mRS 0-2).
  • The median prehospital infusion exposure prior to thrombolysis start was 93 minutes.
  • Overall 90-day outcomes did not show significant clinical benefit from magnesium compared to placebo.

Why it matters

Understanding the potential for prehospital neuroprotective therapies like magnesium sulfate could enhance treatment strategies for acute ischemic stroke, particularly in optimizing the timing of thrombolytic therapy.

Source

PubMed · PMID 42497969

Published in J Stroke Cerebrovasc Dis. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.